- Report
- February 2026
- 281 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 365 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 267 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 582 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 243 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 287 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 267 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 488 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 377 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 383 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 287 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 386 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 142 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 390 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 282 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 575 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 419 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 395 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 395 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 483 Pages
Global
From €5120EUR$5,850USD£4,451GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more